Pancreatic study was just for safety. Phase 1
There is a larger trial with dosage increased coming. Buy!
There is a larger trial with dosage increased coming. Buy!
Thoughts?
We have only just begun.
I wanted to buy a dip before asco!
Lol! These shorts just dont get it
Great time to buy buy buy!
Buy as much as your heart desires!
Its clearly shorts.
This bodes well for Drts.
Merck’s price tag “sweet spot” for potential deals reaches up to $15 billion, CEO Robert Davis said Thursday, as the company digests recent Terns and Cidara buyouts. But he’s not ruling out even bigger buys.
“From a size perspective, we continue to look anywhere in the $1 [billion] to $15 billion range, with that kind of being the sweet spot,” Davis said on the pharma’s quarterly earnings call on Thursday. “But as we’ve consistently said, we have the capacity to go beyond that for the right strategic deal and we will if and when we see that.”